Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 826 to 840 of 1490 results for patients and public

  1. Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559]

    Awaiting development Reference number: GID-TA11758 Expected publication date: TBC

  2. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

  3. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development Reference number: GID-TA11160 Expected publication date: TBC

  4. Abatacept for treating active idiopathic inflammatory myopathies [TSID10095]

    Awaiting development Reference number: GID-TA10993 Expected publication date: TBC

  5. Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613]

    Awaiting development Reference number: GID-TA11469 Expected publication date: TBC

  6. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

  7. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma [ID6527]

    Awaiting development Reference number: GID-TA11653 Expected publication date: TBC

  8. Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]

    In development Reference number: GID-TA11958 Expected publication date:  21 April 2027

  9. Avexitide for treating hypoglycaemia after bariatric surgery [ID6725]

    Awaiting development Reference number: GID-TA11824 Expected publication date: TBC

  10. Troriluzole for spinocerebellar ataxia [ID6456]

    Awaiting development Reference number: GID-TA11549 Expected publication date: TBC

  11. GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)

    Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.

  12. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  13. Deutetrabenazine for treating tardive dyskinesia [ID6550]

    In development Reference number: GID-TA11718 Expected publication date: TBC

  14. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development Reference number: GID-TA11224 Expected publication date: TBC

  15. Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]

    In development Reference number: GID-TA10966 Expected publication date: TBC